ERBB2 and breast carcinoma: So far, the existing research mainly focused on the specific hotspot mutations in HR+HER2‐ breast cancer, the functional characteristics and clinical significance of rare mutations in the PI3K of HER2+ breast cancer subtype were worthy investigated.